A citation-based method for searching scientific literature

Sarah Jervis, Honglin Song, Andrew Lee, Ed Dicks, Patricia Harrington, Caroline Baynes, Ranjit Manchanda, Douglas F Easton, Ian Jacobs, Paul P D Pharoah, Antonis C Antoniou. J Med Genet 2015
Times Cited: 33







List of co-cited articles
242 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Ranjit Manchanda, Rosa Legood, Matthew Burnell, Alistair McGuire, Maria Raikou, Kelly Loggenberg, Jane Wardle, Saskia Sanderson, Sue Gessler, Lucy Side,[...]. J Natl Cancer Inst 2014
96
36

Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
Karoline B Kuchenbaecker, Susan J Ramus, Jonathan Tyrer, Andrew Lee, Howard C Shen, Jonathan Beesley, Kate Lawrenson, Lesley McGuffog, Sue Healey, Janet M Lee,[...]. Nat Genet 2015
145
33

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Ranjit Manchanda, Kelly Loggenberg, Saskia Sanderson, Matthew Burnell, Jane Wardle, Sue Gessler, Lucy Side, Nyala Balogun, Rakshit Desai, Ajith Kumar,[...]. J Natl Cancer Inst 2014
102
33

Population distribution of lifetime risk of ovarian cancer in the United States.
Celeste Leigh Pearce, Daniel O Stram, Roberta B Ness, Douglas A Stram, Lynda D Roman, Claire Templeman, Alice W Lee, Usha Menon, Peter A Fasching, Jessica N McAlpine,[...]. Cancer Epidemiol Biomarkers Prev 2015
51
30

Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R Frankum, Georgina Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie Snape,[...]. Nat Genet 2011
309
30

Germline RAD51C mutations confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Elise Ruark, Rosa Maria Munoz Xicola, Emma Ramsay, Deborah Hughes, Margaret Warren-Perry, Katie Snape, Diana Eccles, D Gareth Evans,[...]. Nat Genet 2012
162
30

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
201
30

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
30

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Ian J Jacobs, Usha Menon, Andy Ryan, Aleksandra Gentry-Maharaj, Matthew Burnell, Jatinderpal K Kalsi, Nazar N Amso, Sophia Apostolidou, Elizabeth Benjamin, Derek Cruickshank,[...]. Lancet 2016
465
30

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
783
30

Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.
William H Parker, Diane Feskanich, Michael S Broder, Eunice Chang, Donna Shoupe, Cynthia M Farquhar, Jonathan S Berek, JoAnn E Manson. Obstet Gynecol 2013
243
24

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
R Manchanda, A Abdelraheim, M Johnson, A N Rosenthal, E Benjamin, C Brunell, M Burnell, L Side, S Gessler, E Saridogan,[...]. BJOG 2011
72
24

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal,[...]. Proc Natl Acad Sci U S A 2014
191
24


Mutations in BRIP1 confer high risk of ovarian cancer.
Thorunn Rafnar, Daniel F Gudbjartsson, Patrick Sulem, Aslaug Jonasdottir, Asgeir Sigurdsson, Adalbjorg Jonasdottir, Soren Besenbacher, Pär Lundin, Simon N Stacey, Julius Gudmundsson,[...]. Nat Genet 2011
235
21


Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Honglin Song, Ed Dicks, Susan J Ramus, Jonathan P Tyrer, Maria P Intermaggio, Jane Hayward, Christopher K Edlund, David Conti, Patricia Harrington, Lindsay Fraser,[...]. J Clin Oncol 2015
162
21

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
348
21

Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.
Ranjit Manchanda, Matthew Burnell, Kelly Loggenberg, Rakshit Desai, Jane Wardle, Saskia C Sanderson, Sue Gessler, Lucy Side, Nyala Balogun, Ajith Kumar,[...]. J Med Genet 2016
25
28

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018
73
21

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
18

Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
R Manchanda, M Burnell, A Abdelraheim, M Johnson, A Sharma, E Benjamin, C Brunell, E Saridogan, S Gessler, D Oram,[...]. BJOG 2012
37
18

Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
Ranjit Manchanda, Shreeya Patel, Antonis C Antoniou, Ephrat Levy-Lahad, Clare Turnbull, D Gareth Evans, John L Hopper, Robert J Macinnis, Usha Menon, Ian Jacobs,[...]. Am J Obstet Gynecol 2017
28
21

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
472
15

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Valérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, Sophie Grandjouan, Laetitia Huiart, Michel Longy, Rosine Guimbaud, Bruno Buecher, Yves-Jean Bignon, Olivier Caron,[...]. JAMA 2011
576
15

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Saundra S Buys, Edward Partridge, Amanda Black, Christine C Johnson, Lois Lamerato, Claudine Isaacs, Douglas J Reding, Robert T Greenlee, Lance A Yokochi, Bruce Kessel,[...]. JAMA 2011
706
15

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
328
15

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
15


Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Kristin Anderson, Judith S Jacobson, Daniel F Heitjan, Joshua Graff Zivin, Dawn Hershman, Alfred I Neugut, Victor R Grann. Ann Intern Med 2006
117
15

Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
488
15

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
695
15

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Amy Finch, Mario Beiner, Jan Lubinski, Henry T Lynch, Pal Moller, Barry Rosen, Joan Murphy, Parviz Ghadirian, Eitan Friedman, William D Foulkes,[...]. JAMA 2006
384
15

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
564
15

Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
Marc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, Jeanne Mandelblatt, Rachel Nusbaum, An-Tsun Huang, Yaojen Chang, Kristi Graves, Claudine Isaacs, Marie Wood,[...]. J Clin Oncol 2014
148
15

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.
Kelly A Metcalfe, Aletta Poll, Robert Royer, Marcia Llacuachaqui, Anna Tulman, Ping Sun, Steven A Narod. J Clin Oncol 2010
109
15

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005
261
15

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Joanna B Madalinska, Judith Hollenstein, Eveline Bleiker, Marc van Beurden, Heiddis B Valdimarsdottir, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst,[...]. J Clin Oncol 2005
164
15

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Catherine A Shu, Malcolm C Pike, Anjali R Jotwani, Tara M Friebel, Robert A Soslow, Douglas A Levine, Katherine L Nathanson, Jason A Konner, Angela G Arnold, Faina Bogomolniy,[...]. JAMA Oncol 2016
109
15

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
A C Antoniou, A P Cunningham, J Peto, D G Evans, F Lalloo, S A Narod, H A Risch, J E Eyfjord, J L Hopper, M C Southey,[...]. Br J Cancer 2008
299
15

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017
168
15

Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
Ranjit Manchanda, Oleg Blyuss, Faiza Gaba, Vladimir Sergeevich Gordeev, Chris Jacobs, Matthew Burnell, Carmen Gan, Rohan Taylor, Clare Turnbull, Rosa Legood,[...]. J Med Genet 2018
19
26

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
239
12

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.
William H Parker, Michael S Broder, Eunice Chang, Diane Feskanich, Cindy Farquhar, Zhimae Liu, Donna Shoupe, Jonathan S Berek, Susan Hankinson, JoAnn E Manson. Obstet Gynecol 2009
400
12

Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.
Laura J Havrilesky, Gloria Broadwater, Debra M Davis, Kimberly C Nolte, J Cory Barnett, Evan R Myers, Shalini Kulasingam. Gynecol Oncol 2009
78
12

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
861
12

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
Victor R Grann, Priya R Patel, Judith S Jacobson, Ellen Warner, Daniel F Heitjan, Maxine Ashby-Thompson, Dawn L Hershman, Alfred I Neugut. Breast Cancer Res Treat 2011
68
12

Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.
Mary-Claire King, Ephrat Levy-Lahad, Amnon Lahad. JAMA 2014
172
12



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.